

AD \_\_\_\_\_

Award Number: W81XWH-08-1-0181

TITLE: Development of a Conditional Transgenic Mouse Model to Test the Fallopian Tube Origin of Serous Ovarian Cancer

PRINCIPAL INVESTIGATOR: Trevor Shepherd, Ph.D.

CONTRACTING ORGANIZATION: The University of Western Ontario  
Ontario, Canada N6A 5B8

REPORT DATE: March 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE 1 March 2009		2. REPORT TYPE Annual		3. DATES COVERED 1 Mar 2008 – 28 Feb 2009	
4. TITLE AND SUBTITLE  Development of a Conditional Transgenic Mouse Model to Test the Fallopian Tube Origin of Serous Ovarian Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-08-1-0181	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  Trevor Shepherd, Ph.D.  E-Mail: tshephe6@uwo.ca				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  The University of Western Ontario Ontario, Canada, N6A 5B8				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this research study is to generate transgenic mice to specifically address fallopian tube tumorigenesis and test the potential for tubal origin of high-grade serous ovarian cancer observed in patient samples. To this end, we have generated two independent lines of transgenic reporter gene mice using the mouse oviduct-specific glycoprotein-1 (Ovgp1) promoter driving expression of the bacterial beta-galactosidase (lacZ) gene. Transgene expression is readily observed in the oviduct of female mice and is concomitant with the onset of puberty. Expression is specifically localized to the oviductal epithelium lining the lumen. In the highest expressing Ovgp1-lacZ transgenic line, however, expression is also significant in the stroma of the uterus. Ongoing studies are focused on understanding the regulation of transgene expression to develop a better method to restrict expression to the oviduct epithelium specifically. We believe our results will lay the foundation to generate an accurate mouse model to study the tubal origin of serous ovarian cancer in humans.					
15. SUBJECT TERMS serous ovarian cancer, transgenic mice, oviduct-specific glycoprotein-1, lacZ reporter gene, oviduct epithelium, uterus					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  UU	18. NUMBER OF PAGES  8	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	6
References.....	6
Appendices.....	8

## INTRODUCTION:

Serous ovarian cancer represents the most common form of ovarian cancer diagnosed in women[1]. Serous ovarian cancers can be further subdivided into low-grade, borderline, and high-grade serous ovarian cancers. However, current evidence from gynecologic pathologists is that high-grade serous ovarian carcinoma may be a distinct disease[2]. Contrary to the pervasive theory that epithelial ovarian cancer originates from the ovarian surface epithelium (OSE)[3], a more recent hypothesis states that the high-grade serous ovarian cancer may originate in the distal fallopian tube[4]. Precursor lesions in the fallopian tube called tubal intraepithelial neoplasia possess upregulated tumour suppressor p53 expression and mutations in p53 protein[5]. Salpingo-oophorectomy samples from high risk BRCA1+ carriers have increased tubal intraepithelial neoplastic lesions even before ovarian pathology emerges[6, 7]. Thus, perhaps high-grade serous ovarian cancer follows a different pathogenetic program as compared to other ovarian cancer histotypes: the origin of high-grade serous adenocarcinoma is in the distal fallopian tube followed by secondary metastasis to the ovarian surface. Thus, the purpose of this research study is to generate transgenic mice to specifically address fallopian tube tumorigenesis and test the potential for tubal origin of high-grade serous ovarian cancer observed in patient samples. Most efforts to produce mouse models of ovarian tumorigenesis have focused on targeting the mouse OSE with conditional genetic alterations[8-13]. The objective of this research study is to derive an alternative animal model for high-grade serous ovarian carcinoma by targeting the epithelium of the mouse oviduct (homologous to the fallopian tube in women). To achieve this end, we have been testing the facility of the mouse oviduct-specific glycoprotein-1 (*Ovgp1*) gene promoter[14].

## BODY:

### Generation of *Ovgp1-lacZ* transgenic mice

The 2.2 kilobase region of the proximal promoter of the mouse *Ovgp1* gene was isolated by polymerase chain reaction using primers specific for *Ovgp1* and the bacterial phagemid containing this region of the mouse genome. The PCR amplified fragment was cloned into the pSCA vector (Stratagene) by standard TA cloning and subsequently DNA sequenced to confirm that it was *Ovgp1*. The *lacZ* cDNA as well as polyadenylation sequences from SV40 present at the 3' end, were cloned directly into the pSCA-*Ovgp1* plasmid. The resultant pSCA/*Ovgp1-lacZ*/pA plasmid was prepared for linearized DNA microinjection into fertilized one-cell mouse embryos (C57Bl/6 x CBA mice). Microinjections and implantation into recipient female foster mice was performed by the in-house Transgenic and Gene Targeting Facility at the London Regional Cancer Program. Thirty-four offspring were produced after microinjection, and genotyping was performed by Southern blotting using the SV40 polyA cassette as a radiolabelled probe and reconfirmed by PCR analysis using primers specific for the *Ovgp1* promoter (forward primer) and *lacZ* (reverse primer) sequences. For all subsequent genotyping, PCR analysis was performed using these same primers. Genotype analysis revealed that 5 of the 34 offspring carried the *Ovgp1-lacZ* transgene; the positive lines were denoted as 238, 242, 243, 252 & 253. These initial founders were individually mated with wildtype mice to test for germline transmission and to initiate stable lines of *Ovgp1-lacZ* mice. Four of the 5 lines (238, 242, 243 & 252) produced offspring that also harboured the transgene, whereas the 253 line produced very few litters and none had pups with the transgene present in the genome. These four independent *Ovgp1-lacZ* transgenic lines were quickly expanded up to perform preliminary assays to determine whether the transgene is expressed in the reproductive tract.

### Ovgp1-lacZ transgene expression in the female reproductive tract

Since the female reproductive system can already harbour significant levels of endogenous beta-galactosidase activity, several small experiments were performed to determine the optimum conditions to observe bacterial *lacZ*-derived beta-galactosidase activity versus endogenous background activity. Staining was performed at room temperature (~22°C) or 37°C for several hours or over night, and using pH buffers ranging from 6.5 to 8.5. We were able to reduce the endogenous beta-galactosidase activity to undetectable levels in the female reproductive tract of wildtype mice when compared to *Ovgp1-lacZ* expression in transgenics. Analysis of *Ovgp1-lacZ* transgene expression by X-gal staining of wholemounts of female reproductive tracts demonstrated that two of the four lines (238 and 242 lines) possessed detectable transgene expression. Very low levels of positive X-gal staining was observed in the 238 line of female *Ovgp1-lacZ* mice by 8 weeks of age (nearing the end of puberty) and this was restricted to the oviduct (Fig. 1). Strikingly, the 242 line of *Ovgp1-lacZ* mice exhibited very strong transgene expression, where positive X-gal staining was generated within hours after starting the assay. *Ovgp1-lacZ* expression in line 242 female mice is first observed as early as 5 weeks of age (the early stages of puberty in female mice), and is tremendously upregulated by 8 and 12 weeks of age (Fig. 1). To further investigate the cells that are expressing the *Ovgp1-lacZ* transgene, frozen sections were prepared from 12-week-old female 242 line transgenic mice. The sections were subsequently processed for X-gal staining and counterstained with eosin. Positive transgene expression was readily observed in the epithelium lining the lumen of the oviduct (Fig. 1). Interestingly, we also determined that the transgene is expressed in cells of the stroma underlying the uterine myometrium (data not shown). Thus, we have determined that the mouse *Ovgp1* promoter may be a useful tool to target genetic manipulation to the female mouse oviduct; however, significant transgene expression can also occur in other cells of the female reproductive tract, namely the uterine stroma compartment. We have since generated an *Ovgp1*-Cre transgene plasmid to follow up on this next strategy.

### KEY RESEARCH ACCOMPLISHMENTS:

- molecular cloning of *Ovgp1-lacZ* reporter gene plasmid
- generation of five independent *Ovgp1-lacZ* transgenic founder lines: lines 238, 242, 243, 252, and 253
- detectable transgene expression in the female reproductive tract of two lines of mice, with one line having low expression restricted to oviduct (line 238) and another with very high levels of expression from oviduct and throughout uterus (line 242)
- preliminary histological analysis to localize transgene expression in the oviduct and uterus of high-expressing 242 line
- molecular cloning of *Ovgp1*-Cre transgene plasmid

### REPORTABLE OUTCOMES:

- generation of two *Ovgp1-lacZ* transgenic lines of reporter gene mice
- applied for CDMRP OCRP Career Development Award application (Title: “Development of novel transgenic mouse models of ovarian cancer”) which was based in part on the work supported from this current CDMRP OCRP Concept Award; the proposal was reviewed as excellent but was not recommended for funding

- the results generated thus far will be presented at the University of Western Ontario Dept. of Obstetrics & Gynaecology Resident Research Day in May 2009 and the Dept. of Oncology Annual Research & Education Day in June 2009; both are local meetings in London, Ontario, Canada


#### CONCLUSION:

The mouse *Ovgpl* promoter may prove useful in targeting specific transgene expression to the oviductal epithelium of female mice in order to generate a much-needed accurate model of a fallopian tube origin of serous ovarian cancer. Since significant transgene expression can also occur in other cells of the female reproductive tract, particularly in the uterine stroma, we are further characterizing the regulation of transgene expression in *Ovgpl-lacZ* transgenic mice which have been generated before proceeding with the production of several additional transgenic mice as detailed in the original Statement of Work.

#### REFERENCES:

1. Ozols, R.F., S.C. Rubin, G.M. Thomas, and S.J. Robboy, *Epithelial ovarian cancer*, in *Principles and Practice of Gynecologic Oncology*, W.J. Hoskins, et al., Editors. 2005, Lippincott Williams & Wilkins: Philadelphia.
2. Levanon, K., C. Crum, and R. Drapkin (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. *J Clin Oncol* **26**: 5284-93.
3. Auersperg, N., A.S. Wong, K.C. Choi, S.K. Kang, and P.C. Leung (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. *Endocr Rev* **22**: 255-88.
4. Crum, C.P., R. Drapkin, A. Miron, T.A. Ince, M. Muto, D.W. Kindelberger, and Y. Lee (2007) The distal fallopian tube: a new model for pelvic serous carcinogenesis. *Curr Opin Obstet Gynecol* **19**: 3-9.
5. Kindelberger, D.W., Y. Lee, A. Miron, M.S. Hirsch, C. Feltmate, F. Medeiros, M.J. Callahan, E.O. Garner, et al. (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. *Am J Surg Pathol* **31**: 161-9.
6. Callahan, M.J., C.P. Crum, F. Medeiros, D.W. Kindelberger, J.A. Elvin, J.E. Garber, C.M. Feltmate, R.S. Berkowitz, et al. (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. *J Clin Oncol* **25**: 3985-90.
7. Crum, C.P., R. Drapkin, D. Kindelberger, F. Medeiros, A. Miron, and Y. Lee (2007) Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. *Clin Med Res* **5**: 35-44.
8. Clark-Knowles, K.V., K. Garson, J. Jonkers, and B.C. Vanderhyden (2007) Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. *Exp Cell Res* **313**: 133-45.
9. Connolly, D.C., R. Bao, A.Y. Nikitin, K.C. Stephens, T.W. Poole, X. Hua, S.S. Harris, B.C. Vanderhyden, et al. (2003) Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIR promoter develop epithelial ovarian cancer. *Cancer Res* **63**: 1389-97.
10. Dinulescu, D.M., T.A. Ince, B.J. Quade, S.A. Shafer, D. Crowley, and T. Jacks (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. *Nat Med* **11**: 63-70.

11. Flesken-Nikitin, A., K.C. Choi, J.P. Eng, E.N. Shmidt, and A.Y. Nikitin (2003) Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. *Cancer Res* **63**: 3459-63.
12. Liang, S., N. Yang, Y. Pan, S. Deng, X. Lin, X. Yang, D. Katsaros, K.F. Roby, et al. (2009) Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. *PLoS ONE* **4**: e4295.
13. Wu, R., N. Hendrix-Lucas, R. Kuick, Y. Zhai, D.R. Schwartz, A. Akyol, S. Hanash, D.E. Misek, et al. (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. *Cancer Cell* **11**: 321-33.
14. Miyoshi, I., K. Takahashi, Y. Kon, T. Okamura, Y. Mototani, Y. Araki, and N. Kasai (2002) Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation. *Mol Reprod Dev* **63**: 168-76.



**Figure 1. Wholemount X-gal staining to visualize *Ovgp1-lacZ* transgene expression in the female mouse reproductive tract.**

Female mice of two different *Ovgp1-lacZ* lines (238, 242) and representative wildtype mice were sacrificed at 3, 5, 8 & 12 weeks of age, as indicated and the dissected intact reproductive tracts were subjected to X-gal staining overnight. Weak staining is seen in the 238 line and very high levels of expression in the 242 line as evidenced by the blue staining of tissue. No staining was observed in the wildtype mice. To localize transgene expression to specific cells within the tissue, cryosections of the female reproductive tract were prepared and subjected to Xgal staining on glass slides. Photos were taken with a stereomicroscope at 40x magnification for wholemounts and inverted microscope at 40x and 200x for sections using ImagePro imaging software.